RLAY: Raymond James Maintains Strong Buy, Raises Price Target to $26

Raymond James maintained its Strong Buy rating on Relay Therapeutics (RLAY) on May 19, 2026, while raising its price target to $26 from $23. This analyst action reflects confidence in the biotech company’s clinical pipeline and precision medicine strategy. RLAY analyst rating updates matter for investors tracking early-stage drug developers. The stock currently trades at $12.07, down 0.25% today, with a market cap of $2.31 billion.

Raymond James Raises RLAY Price Target Amid Pipeline Progress

Raymond James boosted its price target by 13% to $26, signaling optimism about Relay’s clinical programs. The firm maintained its Strong Buy stance, indicating confidence in the company’s ability to advance its lead candidates. RLAY analyst rating reflects the firm’s belief in the precision medicines approach.

Relay focuses on small molecule inhibitors for oncology and genetic diseases. The company’s lead program, RLY-4008, targets FGFR2-altered tumors in a first-in-human trial. RLY-2608 and RLY-1971 represent additional shots on goal in the pipeline.

Financial Position and Market Valuation

Relay trades above its 50-day average of $12.58 and well above its 200-day average of $8.13. The biotech company maintains a strong balance sheet with $3.57 in cash per share and a current ratio of 22.1. These metrics show solid liquidity for funding clinical development.

The company’s market cap of $2.31 billion reflects investor expectations for pipeline success. Meyka AI rates RLAY with a grade of B, suggesting moderate fundamentals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Analyst Consensus and Stock Performance

Raymond James raised its price target to $26 from $23, reflecting confidence in clinical progress. The broader analyst community shows strong support with 11 Buy ratings and 1 Strong Buy rating. This consensus suggests the market sees value in RLAY’s precision medicine approach.

Year-to-date, RLAY has gained 42.7%, though it remains below its 52-week high of $17.32. The stock’s volatility reflects typical biotech risk. RLAY trades in a range where clinical milestones will drive near-term direction.

Clinical Pipeline and Development Timeline

Relay’s pipeline includes three main programs targeting high-value oncology indications. RLY-4008 represents the most advanced candidate in first-in-human testing for FGFR2 mutations. The company also partners with Genentech on RLY-1971 development and commercialization.

Earnings are expected August 6, 2026, which may provide pipeline updates. The company has 259 full-time employees focused on advancing precision medicines. Success in clinical trials will be critical for validating the platform approach.

Final Thoughts

Raymond James’ maintained Strong Buy rating and $26 price target reflects confidence in Relay Therapeutics’ precision medicine platform and clinical pipeline. The 13% price target increase signals optimism about RLY-4008 and companion programs. With a B-grade from Meyka AI and strong analyst consensus, RLAY remains a closely watched biotech name. Investors should monitor clinical trial progress and upcoming earnings for catalysts. The stock’s current valuation offers potential upside if pipeline programs advance successfully, though biotech execution risk remains.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.